Expression of molecular targets for XXXX kinase receptor antagonists in @entity788 .

@entity1 @entity675 @entity788 @entity4562 @entity5 @entity470 @entity3820 @entity2467 @entity669 @entity2213
PURPOSE: Molecular targeting with monoclonal antibodies and @entity669 kinase inhibitors is a novel approach to @entity5 treatment. We have examined the expression of molecular targets in @entity1 with @entity788 , which is necessary to justify additional studies investigating the potential benefit from such treatment. EXPERIMENTAL DESIGN: Thirty-eight @entity5 tissues from @entity788 were examined with immunohistochemistry using specific polyclonal antibodies with regard to the expression pattern of platelet-derived growth factor receptors (PDGFRs) alpha and beta, @entity2467 , and @entity470 ( @entity470 ). RESULTS: All 38 tissue specimens expressed @entity675 on @entity5 cells, and 21 of 37 specimens (57%) expressed @entity675 in @entity5 stroma (1 specimen was nonevaluable). Twenty-eight samples (74%) stained positive for @entity3820 on @entity5 cells, and 36 of 37 samples (97%) stained positive for @entity3820 in the stroma (1 specimen was nonevaluable). Thirty-five @entity5 tissues (92%) stained positive for @entity2467 , and 21 (55%) stained positive for @entity470 on @entity5 cells. No differences were seen between syndromes or between poorly differentiated or well-differentiated @entity5 . Previous treatment did not influence expression pattern. Receptor expression pattern varied considerably between individuals. CONCLUSIONS: We have found that @entity669 kinase receptors PDGFRs alpha and beta, @entity470 , and @entity2467 are expressed in more than half of the @entity1 with endocrine @entity788 . Because these receptors represent molecular targets for @entity2213 and @entity4562 ( @entity669 kinase inhibitors) and IMC-C225 (a monoclonal antibody), we propose that @entity1 suffering from EPTs might benefit from this new treatment strategy. However, because of great variability in receptor expression pattern, all @entity1 ' individual receptor expression should be examined.
